We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+20.65%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$268M
AUM Growth
-$27.7M
(-9.4%)
Cap. Flow
+$8.01M
Cap. Flow
% of AUM
2.98%
Top 10 Holdings %
Top 10 Hldgs %
40.75%
Holding
95
New
14
Increased
33
Reduced
15
Closed
23
Top Buys
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$17.8M |
| 2 |
UroGen Pharma
URGN
|
+$8.17M |
| 3 |
MRSN
Mersana Therapeutics
MRSN
|
+$7.61M |
| 4 |
Gossamer Bio
GOSS
|
+$7.06M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$5.7M |
Top Sells
| 1 |
Schrodinger
SDGR
|
+$10.3M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
+$10.2M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$9.78M |
| 4 |
Krystal Biotech
KRYS
|
+$5.78M |
| 5 |
ETNB
89bio
ETNB
|
+$5.64M |
Sector Composition
| 1 | Healthcare | 99.9% |
| 2 | Consumer Staples | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $20.7M | 7.73% |
1,307,435
-112,565
| -8% | -$1.87M |
|
|
MORF
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $13.5M | 5.04% |
590,829
+338,520
| +134% | +$17.8M |
|
|
MRUS
3
DELISTED
Merus
MRUS
| $11.8M | 4.39% |
500,000
-89,255
| -15% | -$2.16M |
|
|
SLNO
4
DELISTED
Soleno Therapeutics
SLNO
| $10.9M | 4.07% |
+370,000
| New | +$2.24M |
|
|
ITCI
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.9M | 4.05% |
208,730
+10,007
| +5% | +$583K |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| $8.8M | 3.28% |
590,000
+430,000
| +269% | +$5.7M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.71M | 3.25% |
200,000
+108,787
| +119% | +$3.88M |
|
|
PSTX
8
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $8.49M | 3.16% |
3,567,985
+622,037
| +21% | +$1.3M |
|
|
9
Krystal Biotech
KRYS
$9.79B
| $8.3M | 3.09% |
71,531
-47,410
| -40% | -$5.78M |
|
10
Biogen
BIIB
$28.1B
| $7.21M | 2.69% |
28,069
+1,215
| +5% | +$325K |
|
|
11
UroGen Pharma
URGN
$1.88B
| $7.13M | 2.66% |
+508,883
| New | +$8.17M |
|
12
United Therapeutics
UTHR
$22.2B
| $7.1M | 2.64% |
31,424
+1,395
| +5% | +$321K |
|
13
Praxis Precision Medicines
PRAX
$8.98B
| $7.04M | 2.62% |
274,528
+42,784
| +18% | +$809K |
|
14
Oric Pharmaceuticals
ORIC
$1.11B
| $6.8M | 2.53% |
1,123,345
-327,477
| -23% | -$2.68M |
|
15
Crinetics Pharmaceuticals
CRNX
$8.88B
| $6.54M | 2.44% |
+220,000
| New | +$4.53M |
|
16
Cogent Biosciences
COGT
$6.57B
| $6.35M | 2.37% |
651,372
+31,372
| +5% | +$372K |
|
|
MRSN
17
DELISTED
Mersana Therapeutics
MRSN
| $6.35M | 2.37% |
200,000
+160,000
| +400% | +$7.61M |
|
18
Rhythm Pharmaceuticals
RYTM
$7.42B
| $5.97M | 2.23% |
260,537
+144,369
| +124% | +$3.23M |
|
19
MacroGenics
MGNX
$270M
| $5.89M | 2.19% |
1,264,158
+48,483
| +4% | +$241K |
|
20
BioCryst Pharmaceuticals
BCRX
$2.41B
| $5.61M | 2.09% |
791,671
+30,767
| +4% | +$221K |
|
|
NVO
21
Novo Nordisk
NVO
$222B
| $5.46M | 2.03% |
+60,000
| New | +$5.29M |
|
22
Veracyte
VCYT
$4.67B
| $5.35M | 1.99% |
239,571
+10,120
| +4% | +$260K |
|
|
23
Gossamer Bio
GOSS
$65M
| $5.11M | 1.9% |
+6,130,268
| New | +$7.06M |
|
24
Olema Pharmaceuticals
OLMA
$1.04B
| $5.04M | 1.88% |
407,801
+17,335
| +4% | +$177K |
|
25
Humana
HUM
$48.3B
| $4.87M | 1.81% |
+10,000
| New | +$4.7M |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA